Aigenpulse Updates its CytoML Experiment Suite with the CytoML 5.2
With new unbiased analysis features and an easy-to-use interface, the CytoML 5.2 uses batch processing to engage a range of parameters used simultaneously for better data representation.
Aigenpulse launched the CytoML 5.2, an update to its CytoML Experiment Suite, an automated machine learning solution aimed at streamlining and automating cytometry analysis at scale and replacing manual gating processes.
The new addition works to automate every stage in the flow cytometry data lifecycle by increasing the throughput of data processing and analytics by as much as 600%, increasing the accuracy, reproducibility, and quality of flow cytometry data. The new system also enables the reuse of processed cytometry data, the integration of population counts identified by manual gating to increase the value of the data, and allowing for cross-project analysis.
With new unbiased analysis features and an easy-to-use interface, the CytoML 5.2 uses a batch processing tool to engage a range of parameters used simultaneously to aid scientists in finding the best representation of their data. After significant clusters have been pinpointed, these clusters can be overlaid with marker expression and many types of meta-data to drive hypothesis testing. Meanwhile, the unbiased analysis features simplify the process of assigning identities to populations from clustering outputs.
“Unbiased analysis tools allow complex multi-dimensional data to be simplified, unified, processed, and visualized so that it can be more easily explored and compared,” said Satnam Surae, chief product officer at Aigenpulse, in an April 27, 2021 company press release. “This kind of analysis can be very useful in exploring data without any prior assumptions, as a means to uncover novel insights. It is a complementary technique to semi-automated approaches and is interoperable within the CytoML 5.2 Suite, enabling comparison and validation.”
Source: Aigenpulse
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
